Conditions: Iron Overload After Hematopoietic Stem Cell Transplantation (HSCT) in Patients With Beta-thalassemia Major
Keywords: hematopoietic stem cell transplantation, beta-thalassemia major, deferasirox, iron overload
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 27
Healthy volunteers: no

Brief summary:
This was a prospective, single-arm, multicenter, national, phase II clinical study. The purpose of this Phase II study was to examine the safety and efficacy of deferasirox to decrease iron overload (IOL) in the posttransplant period in patients with beta-thalassemia major.

Detailed description:

Arms:
arm 1: Oral dose of ICL670 at 10 mg/kg daily

Interventions: intervention 1: ICL670
Intervention descriptions: intervention 1: Oral dose of ICL670 at 10 mg/kg daily

Protocol document: